Form 4: Codexis CEO Alison Moore Granted 993,000 Stock Options

Codexis, Inc. President and CEO Alison Moore was granted 993,000 stock options with an exercise price of $1.07, vesting over four years.

Summary

• Alison Moore, President and CEO of Codexis, Inc. (CDXS), was granted 993,000 stock options.
• The stock options have an exercise price of $1.07 per share.
• The grant date for these options is February 23, 2026, and they expire on February 23, 2036.
• The options vest over a four-year period: 25% on the first anniversary of the grant date, and 1/48th of the original number of shares monthly thereafter.
• Vesting is contingent upon Alison Moore's continued employment through the applicable vesting dates.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies a standard executive compensation practice that aligns the CEO's long-term interests with the company's stock performance, without directly indicating operational performance.

Positives

• The grant of a significant number of stock options to the President and CEO aligns her long-term incentives with shareholder value creation.
• The 10-year expiration period for the options provides ample time for potential stock appreciation.

Risks

• The value of the stock options is entirely dependent on Codexis's stock price appreciating above the $1.07 exercise price; if the stock price does not increase, the options may expire worthless.
• The vesting schedule requires Alison Moore's continued employment, meaning the full benefit of the options is not realized if her employment ceases before full vesting.

Future Outlook

This filing details the vesting schedule for the granted stock options, which extends over four years, contingent on continued employment.

Industry Context

StockSavvy.ai notes that executive stock option grants are a common practice in the biotechnology and specialty chemicals sectors, aiming to align executive incentives with long-term shareholder value. The structure of this grant, with a multi-year vesting schedule, is typical for retaining key leadership.

Comparison to Industry Standards

• The structure of the stock option grant, including a multi-year vesting schedule (25% on the first anniversary, then monthly thereafter) and a 10-year expiration period, aligns with common industry practices for executive compensation in the biotechnology and specialty chemicals sectors.
• Companies such as Amyris, Inc. or Ginkgo Bioworks Holdings, Inc. often utilize similar long-term incentive structures to retain key executives and align their interests with shareholder value creation.

Stakeholder Impact

• Shareholders: Potential for increased alignment between the CEO's incentives and long-term shareholder value.
• Management: The CEO's compensation package is enhanced, providing a long-term incentive for retention and performance.

Next Steps

• Continued employment of Alison Moore to ensure the vesting of the granted options.
• Future reporting of any sales or further acquisitions of Codexis securities by Alison Moore via subsequent Form 4 filings.

Key Dates

Recommendation

This Form 4 filing reports a routine executive stock option grant, which is a standard component of compensation packages designed to align management incentives with long-term shareholder value. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as it reflects no significant new catalysts for a buy or sell decision based solely on this filing.

Keywords

Codexis, CDXS, Stock Options, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Vesting Schedule, Alison Moore